No differences in β-methylation values between colon adenocarcinomas and adjacent controls existed within the proximal region of SPRY4's promoter, which spans two CpG islands near the transcriptional start site (TSS) (Figure 2). This evidence concerns the gene SPRY4 and colon adenocarcinoma.